![William T. Hayes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Ed Kania | M | 66 |
TransMedics, Inc.
![]() TransMedics, Inc. Medical SpecialtiesHealth Technology TransMedics, Inc. manufactures and develops medical devices. It offers a portable warm blood perfusion system designed to maintain organs in a functioning state outside the human body during transport from organ donor to recipient. The firm’s products are used in heart, lung, liver, and kidney transplants. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. | 22 jaar |
Tamer Khayal | M | 55 |
TransMedics, Inc.
![]() TransMedics, Inc. Medical SpecialtiesHealth Technology TransMedics, Inc. manufactures and develops medical devices. It offers a portable warm blood perfusion system designed to maintain organs in a functioning state outside the human body during transport from organ donor to recipient. The firm’s products are used in heart, lung, liver, and kidney transplants. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. | 23 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Todd F. Davenport | M | 73 |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 jaar |
Gregory Lambrecht | M | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | - |
Richard T. Spencer | M | 87 |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 jaar |
Jonathan M. Rourke | M | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 jaar |
Katharine M. Stohlman | F | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 10 jaar |
Christopher D. Hutchins | M | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 8 jaar |
David S. Marks | M | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 7 jaar |
John Liddicoat | M | 60 |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 jaar |
William Cohn | M | 64 |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 16 jaar |
A. Marc Gillinov | M | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 13 jaar |
Christine L. Brauer | M | - |
TransMedics, Inc.
![]() TransMedics, Inc. Medical SpecialtiesHealth Technology TransMedics, Inc. manufactures and develops medical devices. It offers a portable warm blood perfusion system designed to maintain organs in a functioning state outside the human body during transport from organ donor to recipient. The firm’s products are used in heart, lung, liver, and kidney transplants. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA. | - |
Stanley B. Kyi | M | - |
Viacor, Inc.
![]() Viacor, Inc. Medical SpecialtiesHealth Technology Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of heart valve disease contributing to congestive heart failure. Currently, they are focused on the development of a minimally invasive cardiac valve repair system to treat congestive heart failure (CHF) patients afflicted with mitral regurgitation (MR), or 'leaky' mitral valves - a common problem among patients with CHF. Over 750,000 patients in the United States alone have associated functional MR and their mortality rate is double that of patients without MR. Their goal is to provide a new therapeutic alternative that significantly expands the potential to treat this large heart failure population without the risks associated with current surgical procedures. Viacor's Percutaneous Transvenous Mitral Annuloplasty (PTMA®) device has the potential to offer effective treatment with minimal intervention. | 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 14 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- William T. Hayes
- Persoonlijk netwerk